NCI-2024-09782

An Open-label Phase 1 Study of ASP4396 in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

This is a Phase 1 research study testing the new drug ASP4396 in patients with advanced solid tumors that have a specific mutation in the KRAS gene (G12D). The primary goals of this trial are to determine a safe and effective dose of ASP4396 and to assess how the body handles the drug.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

KRAS: A KRAS mutation is a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06364696

Clinical Trial Site: Sinai

To see all available clinical trials click here.